Financial Personal
Aegis Life and Entos Complete Phase 1 Enrollment of Clinical Trial for COVID-19 Vaccine Booster
Covigenix VAX-002 shows significant promise as a novel DNA vaccine to stimulate immunity against circulating strains of SARS-CoV-2 in animal models Data published in the print edition of Cell today describes the Fusogenix PLV platform for safe and ef
SAN DIEGO, Calif. & EDMONTON, Alberta -- Aegis Life, Inc. (Aegis) and its partner Entos® Pharmaceuticals (Entos), announced today that the Phase 1 portion of a Phase 1/2 clinical trial of Covigenix VAX-002 ( NCT06436911) evaluating it as a COVID-19 booster vaccine is fully enrolled. Covigenix VAX-002 is formulated using the Entos Fusogenix™ PLV™ technology and plasmid DNA expressing key SARS-CoV-2 antigens to protect against the current circulating omicron strains of SARS-CoV-2. Enrollment in the phase 1 portion of the study was initiated in August 2024. The development of the Fusogenix platform for DNA delivery is detailed in a publication released today in print in Cell. Read More
